Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00784_DB00930_nanopub.RAV8qnCeF2IpKdpdYyDK4-8d4cv8CWlULlMAlkfMfpUZY#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00784_DB00930 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00784_DB00930 label "DDI between Mefenamic acid and Colesevelam - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. [drugbank_resource:DB00784_DB00930]" assertion.
- drugbank_resource:DB00784_DB00930 identifier "drugbank_resource:DB00784_DB00930" assertion.
- drugbank_resource:DB00784_DB00930 title "DDI between Mefenamic acid and Colesevelam - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam." assertion.
- drugbank:DB00930 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00784_DB00930 assertion.
- drugbank:DB00784 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00784_DB00930 assertion.